• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Minerva Surgical Inc. (Amendment)

    2/10/23 4:05:53 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology
    Get the next $UTRS alert in real time by email
    SC 13G/A 1 d232039dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Minerva Surgical, Inc.

    (Name of Issuer)

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

    60343F106

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 60343F106    13G    Page 2  of 5 Pages

     

      1.    

      NAME OF REPORTING PERSON

     

      CVF, LLC

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☐

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5.    

      SOLE VOTING POWER

     

      2,259,685(1)

       6.  

      SHARED VOTING POWER

     

      —

       7.  

      SOLE DISPOSITIVE POWER

     

      2,259,685(1)

       8.  

      SHARED DISPOSITIVE POWER

     

      —

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,259,685(1)

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      7.8%(1)

    12.  

      TYPE OF REPORTING PERSON

     

      OO

     

    (1)

    As of December 31, 2022. Percent of class is less than 5% as of filing date. See Item 5.

     

    - 2 -


    CUSIP No. 60343F106    13G    Page 3  of 5 Pages

     

    Item 1(a).

      

    Name of Issuer:

      

    Minerva Surgical, Inc.

    Item 1(b).

      

    Address of Issuer’s Principal Executive Offices:

      

    4255 Burton Drive, Santa Clara, CA 95054

    Item 2(a).

      

    Name of Person Filing:

      

    CVF, LLC (“CVF”)

    Item 2(b).

      

    Address of Principal Business Office or, if none, Residence:

      

    222 N. LaSalle Street, Suite 2000, Chicago, Illinois 60601

    Item 2(c).

      

    Citizenship:

      

    Delaware

    Item 2(d).

      

    Title of Class of Securities:

      

    Common Stock, $0.001 par value per share

    Item 2(e).

      

    CUSIP Number:

      

    45332Y109

    Item 3.

      

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), indicate type of person filing.

      

    Not applicable.

    Item 4.

      

    Ownership.

      

    (a)

      

    Amount beneficially owned: See row 9 of the cover page.

      

    (b)

      

    Percent of class: See row 11 of the cover page.

      

    (c)

      

    Number of shares as to which such person has:

         

    (i) Sole power to vote or direct the vote:  See row 5 of the cover page.

         

    (ii)  Shared power to vote or direct the vote:  See row 6 of the cover page.

         

    (iii)  Sole power to dispose or to direct the disposition of:  See row 7 of the cover page.

         

    (iv) Shared power to dispose or to direct the disposition of:  See row 8 of the cover page.

     

    - 3 -


    CUSIP No. 60343F106    13G    Page 4  of 5 Pages

     

       Percent of class is based on (i) the number of shares held by CVF as of December 31, 2022 and (ii) the number of shares of common stock outstanding as of November 2, 2022 (28,968,530 shares) as reported by the Issuer in its most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022.

    Item 5.

       Ownership of Five Percent or Less of a Class.
       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following  ☒

    Item 6.

       Ownership of More than Five Percent on Behalf of Another Person.
       Not applicable.

    Item 7.

       Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       Not applicable.

    Item 8.

       Identification and Classification of Members of the Group.
       Not applicable.

    Item 9.

       Notice of Dissolution of Group.
       Not applicable.

    Item 10.

       Certifications.
       Not applicable.

     

    - 4 -


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 10, 2023     CVF, LLC
        By:   /s/ Richard H. Robb
        Name: Richard H. Robb
        Title: Manager

     

    - 5 -

    Get the next $UTRS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UTRS

    DatePrice TargetRatingAnalyst
    3/9/2022$17.00 → $12.00Overweight
    Piper Sandler
    12/3/2021$17.00 → $12.00Outperform
    SVB Leerink
    11/16/2021$17.00Outperform
    SVB Leerink
    11/16/2021$15.00Buy
    UBS
    11/16/2021$14.00Overweight
    JP Morgan
    11/16/2021$17.00Overweight
    Piper Sandler
    More analyst ratings

    $UTRS
    SEC Filings

    View All

    SEC Form 15-12G filed by Minerva Surgical Inc.

    15-12G - MINERVA SURGICAL INC (0001452965) (Filer)

    1/4/24 4:32:00 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology

    SEC Form 25 filed by Minerva Surgical Inc.

    25 - MINERVA SURGICAL INC (0001452965) (Filer)

    12/26/23 4:30:25 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology

    SEC Form S-8 POS filed by Minerva Surgical Inc.

    S-8 POS - MINERVA SURGICAL INC (0001452965) (Filer)

    12/26/23 12:05:19 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology

    $UTRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Minerva Surgical Reports Third Quarter 2023 Financial Results

    SANTA CLARA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported third quarter financial results for the period ended September 30, 2023. Third Quarter Highlights: Reported revenue of $12.0 million in the third quarter of 2023, compared with revenue of $12.6 million in the third quarter of 2022Increased Symphion product revenue by 19% compared to the third quarter of 2022 "As we head into the fourth quarter of 2023, I am very pleased with the progress we have made to date in expanding the reach of our Sym

    11/13/23 4:01:00 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology

    Minerva Surgical Reports Second Quarter 2023 Financial Results

    SANTA CLARA, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported second quarter financial results for the period ended June 30, 2023. Second Quarter Highlights: Reported revenue of $13.4 million in the second quarter of 2023, compared with revenue of $13.0 million in the second quarter of 2022Increased both Symphion and Minerva ES product revenue by 7% compared to the second quarter of 2022Realigned the commercial organization to better serve customer needs and drive sustainable growth "From o

    8/2/23 4:01:00 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology

    Minerva Surgical Reports First Quarter 2023 Financial Results

    SANTA CLARA, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported first quarter financial results for the period ended March 31, 2023. First Quarter and Recent Business Highlights: Reported revenue of $12.5 million in the first quarter of 2023, compared with revenue of $10.9 million in the first quarter of 2022Increased revenue for all product lines compared to the first quarter of 2022, with Symphion increasing 20% and Minerva ES increasing 18%Appointed Todd Usen as Chief Executive Officer at the start of 2023 co

    5/2/23 4:01:00 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology

    $UTRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler reiterated coverage on Minerva Surgical with a new price target

    Piper Sandler reiterated coverage of Minerva Surgical with a rating of Overweight and set a new price target of $12.00 from $17.00 previously

    3/9/22 6:38:44 AM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology

    SVB Leerink reiterated coverage on Minerva Surgical with a new price target

    SVB Leerink reiterated coverage of Minerva Surgical with a rating of Outperform and set a new price target of $12.00 from $17.00 previously

    12/3/21 9:34:35 AM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology

    SVB Leerink initiated coverage on Minerva Surgical with a new price target

    SVB Leerink initiated coverage of Minerva Surgical with a rating of Outperform and set a new price target of $17.00

    11/16/21 7:59:25 AM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology

    $UTRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3: New insider Cohen Daniel claimed ownership of 122,189,638 shares

    3 - MINERVA SURGICAL INC (0001452965) (Issuer)

    3/14/23 5:37:19 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology

    SEC Form 4: New Enterprise Associates 13 Lp bought $5,000,000 worth of shares (24,437,927 units at $0.20)

    4 - MINERVA SURGICAL INC (0001452965) (Issuer)

    2/10/23 9:25:19 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology

    SEC Form 3: New insider Accelmed Partners Ii L.P. claimed ownership of 122,189,638 shares

    3 - MINERVA SURGICAL INC (0001452965) (Issuer)

    2/9/23 4:28:55 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology

    $UTRS
    Financials

    Live finance-specific insights

    View All

    Minerva Surgical Reports Second Quarter 2023 Financial Results

    SANTA CLARA, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported second quarter financial results for the period ended June 30, 2023. Second Quarter Highlights: Reported revenue of $13.4 million in the second quarter of 2023, compared with revenue of $13.0 million in the second quarter of 2022Increased both Symphion and Minerva ES product revenue by 7% compared to the second quarter of 2022Realigned the commercial organization to better serve customer needs and drive sustainable growth "From o

    8/2/23 4:01:00 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology

    Minerva Surgical Reports First Quarter 2023 Financial Results

    SANTA CLARA, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported first quarter financial results for the period ended March 31, 2023. First Quarter and Recent Business Highlights: Reported revenue of $12.5 million in the first quarter of 2023, compared with revenue of $10.9 million in the first quarter of 2022Increased revenue for all product lines compared to the first quarter of 2022, with Symphion increasing 20% and Minerva ES increasing 18%Appointed Todd Usen as Chief Executive Officer at the start of 2023 co

    5/2/23 4:01:00 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology

    Minerva Surgical to Announce First Quarter 2023 Financial Results

    SANTA CLARA, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS), a medical technology company focused on solutions to meet the distinct uterine healthcare needs of women, announced today that it will release its first quarter 2023 financial results on Tuesday, May 2, 2023. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique pe

    4/18/23 4:01:00 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology

    $UTRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Minerva Surgical Inc. (Amendment)

    SC 13D/A - MINERVA SURGICAL INC (0001452965) (Subject)

    9/28/23 4:43:42 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13D/A filed by Minerva Surgical Inc. (Amendment)

    SC 13D/A - MINERVA SURGICAL INC (0001452965) (Subject)

    7/6/23 8:21:56 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13D/A filed by Minerva Surgical Inc. (Amendment)

    SC 13D/A - MINERVA SURGICAL INC (0001452965) (Subject)

    7/6/23 5:19:24 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology

    $UTRS
    Leadership Updates

    Live Leadership Updates

    View All

    Minerva Surgical Announces the Appointment of Kaile Zagger as Chief Commercial Officer

    SANTA CLARA, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, announced today the appointment of Kaile Zagger as its new Chief Commercial Officer. Ms. Zagger's leadership will help guide the strategic growth of the company and advance its position as a leader in women's healthcare solutions. "We are excited to have Kaile as our new Chief Commercial Officer for her proven track record of driving exponential growth and productivity, while delivering bottom line results," said Todd Usen, president and CEO of Minerva Surgical. "Beyond her pro

    3/21/23 4:05:00 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology

    Minerva Surgical Announces Retirement of CEO David Clapper and Appointment of Todd Usen as Company President and CEO

    SANTA CLARA, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that David Clapper, who has served as President and Chief Executive Officer since 2011, has chosen to retire. The Company's board of directors (the Board) has appointed industry executive Todd Usen as President and Chief Executive Officer of Minerva Surgical and a member of the Board to succeed Mr. Clapper effective January 2, 2023. To ensure a smooth leadership transition, Mr. Clapper will continue to serve in his role through Mr. Usen's first day of employment an

    12/28/22 6:00:00 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology

    Minerva Surgical Announces Appointment of Derrick Sung, Ph.D. to Board of Directors

    SANTA CLARA, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) ("Minerva Surgical" or the "Company"), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today announced that the board of directors (the "Board") of Minerva Surgical has appointed Derrick Sung, Ph.D. to serve as a Class II director, with a term expiring at the 2023 annual meeting of stockholders or until his successor has been duly elected and qualified. The Board has affirmatively determined that Dr. Sung is an independent director pursuant to the listing standards of The NASDAQ Stock Market. "We are excited to have Derrick Sung, Ph.D. join the Board of Directo

    7/21/22 8:00:00 AM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology